Mirko Ristanovic
Oncology IDM Access Implementation Lead Pfizer
Mirko Ristanovic is Oncology IDM Access Implementation Lead at Pfizer, where he works at the intersection of market access, HTA, AI transformation, and strategic decision-making across the oncology portfolio. With more than 20 years of experience at Pfizer spanning commercial, pricing, market access, business development, and launch strategy, he brings a broad understanding of how evidence and insights translate into successful market access and value demonstration.
In his current role, Mirko has played a key role in advancing the use of applied and generative AI across market access, embedding AI-enabled decision support into HTA, strategic planning, and launch readiness. He has also led the selection and implementation of digital platforms for access analytics, KPI tracking, and strategic decision-making. His expertise spans indication and launch sequencing, international reference pricing risk mitigation, pricing strategy, HTA, and navigating complex healthcare environments across developed and emerging markets.
Seminars
This hands-on workshop moves beyond AI theory and puts attendees directly into the RWE study lifecycle. Working through practical use cases, participants will explore how AI can be applied across protocol development, statistical planning, data abstraction and evidence generation, while navigating the validation, confidentiality and regulatory challenges that come with implementation. By the end of the session, attendees will have practical prompts, tools and frameworks they can take back to their teams and apply to their own RWE programmes.
Attend this workshop to:
- Work through the RWE study lifecycle and identify where AI can meaningfully accelerate processes without compromising scientific rigour or regulatory requirements.
- Develop and test practical AI prompts and workflows for protocol development, statistical analysis planning and medical record abstraction.
- Build approaches for validating AI-generated outputs, establishing appropriate gold standards and maintaining human oversight before evidence reaches regulatory submission
